Literature DB >> 1803886

Proliferation in pituitary adenomas: measurement by MAb KI 67.

K Kitz1, E Knosp, W T Koos, A Korn.   

Abstract

The monoclonal antibody MAb KI 67 reacts with a nuclear antigen throughout the entire cell cycle and allows easy evaluation of proliferating tumour cells on routinely prepared smear and frozen sections. 120 pituitary adenomas were investigated by use of the monoclonal antibody KI 67 in a two-step avidin-biotin-peroxidase complex (ABC) technique. The KI 67 labelling index (LI) ranged in all adenomas from 0.2 to 4.6%. In 90 cases of transphenoidally operated adenomas the dura of the sella floor was investigated histologically. Adenomas with histologically proven dural infiltration showed a statistically significant higher KI 67 LI (p less than 0.001) compared to non-invasive adenomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1803886     DOI: 10.1007/978-3-7091-9183-5_11

Source DB:  PubMed          Journal:  Acta Neurochir Suppl (Wien)


  16 in total

1.  The clinical significance of MIB-1 labeling index in pituitary adenomas.

Authors:  Geeta Chacko; Ari G Chacko; Kalman Kovacs; Bernd W Scheithauer; Sunithi Mani; J P Muliyil; M S Seshadri
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

2.  Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis.

Authors:  H Kawamoto; K Kawamoto; T Mizoue; T Uozumi; K Arita; K Kurisu
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

3.  Expression of epithelial cadherin and cavernous sinus invasion in human pituitary adenomas.

Authors:  H Kawamoto; T Mizoue; K Arita; A Tominaga; K Eguchi; K Kurisu
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

4.  Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas.

Authors:  H Kawamoto; T Uozumi; K Kawamoto; K Arita; T Yano; T Hirohata
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

5.  Prognostic criteria in nonfunctioning pancreatic endocrine tumours.

Authors:  S La Rosa; F Sessa; C Capella; C Riva; B E Leone; C Klersy; G Rindi; E Solcia
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

6.  Expression of proliferation markers in human pituitary incidentalomas.

Authors:  Masanori Suzuki; Takeo Minematsu; Kenichi Oyama; Shigeyuki Tahara; Shunsuke Miyai; Naoko Sanno; Robert Yoshiyuki Osamura; Akira Teramoto
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

7.  Proliferation markers in different types of clinically non-secreting pituitary adenomas.

Authors:  S Schreiber; W Saeger; D K Lüdecke
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

8.  Clinical significance of Ki-67 labeling index in pituitary macroadenoma.

Authors:  Kyung-Il Paek; Seon-Hwan Kim; Shi-Hun Song; Seung-Won Choi; Hyeon-Song Koh; Jin-Young Youm; Youn Kim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

9.  Proliferation Markers and Their Uses in the Study of Endocrine Tumors.

Authors:  Giuseppe Pelosi; Giuseppe Zamboni
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

10.  p27(kip1) and Other Cell-Cycle Protein Expression in Normal and Neoplastic Endocrine Tissues.

Authors:  Lori A. Erickson
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.